Loading...

Lawrence Fong, MD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentMedicine
Address513 Parnassus Ave
San Francisco CA 94143
Phone415-514-3160
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Immunotherapy of human bladder cancer
    NIH/NCI R01CA194511Jul 2, 2015 - Jun 30, 2020
    Role: Principal Investigator
    Prostatitis and Prostate Cancer Development
    NIH/NCI R01CA163012Sep 1, 2012 - Jun 30, 2017
    Role: Principal Investigator
    Prostate Cancer Immunotherapy
    NIH/NCI R01CA136753Mar 1, 2009 - Feb 28, 2014
    Role: Principal Investigator
    Dendritics Cell Immunotherapy for Colorectal Cancer
    NIH/NCI R01CA102303Apr 1, 2004 - Mar 31, 2009
    Role: Principal Investigator
    DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCER
    NIH/NCI K23CA082584Jul 6, 1999 - Jun 30, 2004
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017 Jan 10. PMID: 28111070.
      View in: PubMed
    2. Fong L, Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M. T cell repertoire diversification is associated with immune related toxicities following CTLA-4 blockade in cancer patients. Cancer Res. 2016 Dec 28. PMID: 28031229.
      View in: PubMed
    3. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016; 4:92. PMID: 28031820.
      View in: PubMed
    4. Kim W, Fong L. Can Prostate Cancer Really Respond to Immunotherapy? J Clin Oncol. 2017 Jan; 35(1):4-5. PMID: 28034060.
      View in: PubMed
    5. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 Sep 29. PMID: 27688020.
      View in: PubMed
    6. Wattenberg MM, Fong L, Madan RA, Gulley JL, et al. Immunotherapy in genitourinary malignancies. Curr Opin Urol. 2016 Jul 28. PMID: 27471994.
      View in: PubMed
    7. Sheikh NA, Cham J, Zhang L, DeVries T, Letarte S, Pufnock J, Hamm D, Trager JB, Fong L. Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects. Cancer Res. 2016 Jul 1; 76(13):3711-8. PMID: 27216195.
      View in: PubMed
    8. Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 May 11. PMID: 27169994.
      View in: PubMed
    9. Wei XX, Fong L, Small EJ. Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert Opin Biol Ther. 2016 Mar; 16(3):421-32. PMID: 26698365.
      View in: PubMed
    10. Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE. GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. Oncoimmunology. 2016 Apr; 5(4):e1101204. PMID: 27141383.
      View in: PubMed
    11. Wei XX, Fong L, Small EJ. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015 Dec; 14(12):1529-41. PMID: 26488270.
      View in: PubMed
    12. Oh DY, Venook AP, Fong L. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw. 2015 Aug; 13(8):970-8. PMID: 26285242.
      View in: PubMed
    13. Landegren N, Sharon D, Shum AK, Khan IS, Fasano KJ, Hallgren Å, Kampf C, Freyhult E, Ardesjö-Lundgren B, Alimohammadi M, Rathsman S, Ludvigsson JF, Lundh D, Motrich R, Rivero V, Fong L, Giwercman A, Gustafsson J, Perheentupa J, Husebye ES, Anderson MS, Snyder M, Kämpe O. Transglutaminase 4 as a prostate autoantigen in male subfertility. Sci Transl Med. 2015 Jun 17; 7(292):292ra101. PMID: 26084804.
      View in: PubMed
    14. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16. PMID: 25968455; PMCID: PMC4561203 [Available on 09/01/16].
    15. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 1; 21(17):3862-9. PMID: 25925891.
      View in: PubMed
    16. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. PMID: 25336698; PMCID: PMC4277885 [Available on 12/15/15].
    17. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11). PMID: 25255802; PMCID: PMC4241888.
    18. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014 May 28; 6(238):238ra70. PMID: 24871131; PMCID: PMC4558099.
    19. Khan IS, Mouchess ML, Zhu ML, Conley B, Fasano KJ, Hou Y, Fong L, Su MA, Anderson MS. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J Exp Med. 2014 May 5; 211(5):761-8. PMID: 24752296; PMCID: PMC4010907.
    20. Friedlander TW, Fong L. The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1104-6. PMID: 24616311.
      View in: PubMed
    21. Cheng ML, Fong L. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol. 2014 Mar; 15(1):115-26. PMID: 24402184; PMCID: PMC4523381.
    22. Lou DY, Fong L. Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. Urol Oncol. 2016 Apr; 34(4):182-92. PMID: 24495446.
      View in: PubMed
    23. Cheng ML, Fong L. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol. 2014 Jan 7; 3:329. PMID: 24432249; PMCID: PMC3882875.
    24. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34. PMID: 24022191; PMCID: PMC3790192.
    25. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012 Oct 1; 189(7):3759-66. PMID: 22956585; PMCID: PMC3448828.
    26. Kwek SS, Cha E, Fong L. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer. 2012 Apr; 12(4):289-97. PMID: 22378189; PMCID: PMC3433280.
    27. Taccioli C, Chen H, Jiang Y, Liu XP, Huang K, Smalley KJ, Farber JL, Croce CM, Fong LY. Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature. Oncogene. 2012 Oct 18; 31(42):4550-8. PMID: 22179833; PMCID: PMC3310953.
    28. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9. PMID: 21971890.
      View in: PubMed
    29. Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol. 2011 Sep 20; 29(27):3677-85. PMID: 21825260; PMCID: PMC3675707.
    30. Kapadia D, Sadikovic A, Vanloubbeeck Y, Brockstedt D, Fong L. Interplay between CD8a+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses. PLoS One. 2011; 6(4):e19376. PMID: 21559416; PMCID: PMC3084837.
    31. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200. PMID: 21387258.
      View in: PubMed
    32. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601. PMID: 20978464; PMCID: PMC4296579.
    33. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P, Blelloch R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011 Jan 15; 71(2):550-60. PMID: 21098088; PMCID: PMC3022112.
    34. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14. PMID: 20884247.
      View in: PubMed
    35. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010 Aug; 10(8):1870-80. PMID: 20659093; PMCID: PMC2911648.
    36. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20; 28(21):3485-90. PMID: 20498386.
      View in: PubMed
    37. DeVoss JJ, LeClair NP, Hou Y, Grewal NK, Johannes KP, Lu W, Yang T, Meagher C, Fong L, Strauss EC, Anderson MS. An autoimmune response to odorant binding protein 1a is associated with dry eye in the Aire-deficient mouse. J Immunol. 2010 Apr 15; 184(8):4236-46. PMID: 20237294; PMCID: PMC2851482.
    38. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8. PMID: 20159824; PMCID: PMC2849769.
    39. Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun; 59(6):943-53. PMID: 20140431; PMCID: PMC3038205.
    40. Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther. 2010 Feb; 12(1):77-85. PMID: 20140819.
      View in: PubMed
    41. Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol. 2010 Mar 1; 28(7):1085-7. PMID: 20100956.
      View in: PubMed
    42. Shum AK, DeVoss J, Tan CL, Hou Y, Johannes K, O'Gorman CS, Jones KD, Sochett EB, Fong L, Anderson MS. Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Sci Transl Med. 2009 Dec 2; 1(9):9ra20. PMID: 20368189; PMCID: PMC2856693.
    43. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
    44. Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L. An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest. 2009 Jul; 119(7):2031-41. PMID: 19603556; PMCID: PMC2701875.
    45. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15. PMID: 19147575.
      View in: PubMed
    46. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008 Nov 10; 26(32):5275-83. PMID: 18838703.
      View in: PubMed
    47. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83. PMID: 18523152; PMCID: PMC2515138.
    48. Bergsland EK, Ko AH, Tempero MA, Whittaker K, Weber T, Fong L, Park JW, Yeh BM, Hanahan D, Venook AP. Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):14620. PMID: 27950279.
      View in: PubMed
    49. Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008 Mar 4; 105(9):3509-14. PMID: 18303116; PMCID: PMC2265147.
    50. Hou Y, Kavanagh B, Fong L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol. 2008 Feb 1; 180(3):1526-34. PMID: 18209048.
      View in: PubMed
    51. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol. 2007 Dec; 178(6):2372-6; discussion 2377. PMID: 17936834.
      View in: PubMed
    52. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007 Oct; 30(7):762-72. PMID: 17893568.
      View in: PubMed
    53. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep. 2007 May; 9(3):226-33. PMID: 17430695.
      View in: PubMed
    54. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5. PMID: 17363537.
      View in: PubMed
    55. McCorkell KA, Mancini R, Siprashvili Z, Barnoski BL, Iliopoulos D, Siracusa LD, Zanesi N, Croce CM, Fong L, Druck T, Huebner K. Influence of a nonfragile FHIT transgene on murine tumor susceptibility. Cytogenet Genome Res. 2007; 118(2-4):196-203. PMID: 18000371.
      View in: PubMed
    56. DeVoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi RR, Caspi R, Fong L, Anderson MS. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med. 2006 Nov 27; 203(12):2727-35. PMID: 17116738; PMCID: PMC2118158.
    57. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9. PMID: 16796694.
      View in: PubMed
    58. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 1; 107(1):67-74. PMID: 16736512.
      View in: PubMed
    59. Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol. 2006 Jun; 175(6):2087-91. PMID: 16697809.
      View in: PubMed
    60. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul; 14(1):107-17. PMID: 16690359.
      View in: PubMed
    61. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep. 2006 May; 7(3):239-46. PMID: 16630528.
      View in: PubMed
    62. Kapadia D, Fong L. CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol. 2005 Dec 10; 23(35):8926-8. PMID: 16204008.
      View in: PubMed
    63. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol. 2003 Oct; 30(5):649-58. PMID: 14571412.
      View in: PubMed
    64. Engleman EG, Fong L. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol. 2003 Jan; 106(1):10-5. PMID: 12584045.
      View in: PubMed
    65. Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J Virol. 2002 Nov; 76(21):11033-41. PMID: 12368346; PMCID: PMC136607.
    66. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood. 2002 Mar 1; 99(5):1676-82. PMID: 11861283.
      View in: PubMed
    67. Fong LY, Nguyen VT, Farber JL. Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. J Natl Cancer Inst. 2001 Oct 17; 93(20):1525-33. PMID: 11604475.
      View in: PubMed
    68. Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, Vecchione A, Baffa R, Trapasso F, During MJ, Huebner K, Croce CM. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci U S A. 2001 Mar 13; 98(6):3346-51. PMID: 11248081; PMCID: PMC30656.
    69. Fong L, Nguyen VT, Farber JL, Huebner K, Magee PN. Early deregulation of the the p16ink4a-cyclin D1/cyclin-dependent kinase 4-retinoblastoma pathway in cell proliferation-driven esophageal tumorigenesis in zinc-deficient rats. Cancer Res. 2000 Aug 15; 60(16):4589-95. PMID: 10969811.
      View in: PubMed
    70. Werner NS, Siprashvili Z, Fong LY, Marquitan G, Schröder JK, Bardenheuer W, Seeber S, Huebner K, Schütte J, Opalka B. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. Cancer Res. 2000 Jun 1; 60(11):2780-5. PMID: 10850413.
      View in: PubMed
    71. Fong L, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Huebner K. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci U S A. 2000 Apr 25; 97(9):4742-7. PMID: 10758156; PMCID: PMC18303.
    72. Bikle DD, Halloran B, Fong L, Steinbach L, Shellito J. Elevated 1,25-dihydroxyvitamin D levels in patients with chronic obstructive pulmonary disease treated with prednisone. J Clin Endocrinol Metab. 1993 Feb; 76(2):456-61. PMID: 8432789.
      View in: PubMed
    73. Fong LY, Lee JS, Chan WC, Newberne PM. Zinc deficiency and the development of esophageal and forestomach tumors in Sprague-Dawley rats fed precursors of N-nitroso-N-benzylmethylamine. J Natl Cancer Inst. 1984 Feb; 72(2):419-25. PMID: 6582327.
      View in: PubMed
    74. Lin HJ, Fong LY. Effects of oxygen depletion on in vitro metabolism of dimethylnitrosamine in microsomes from rat liver and human tissues. J Natl Cancer Inst. 1980 Nov; 65(5):877-83. PMID: 6933257.
      View in: PubMed
    75. Fong LY, Sivak A, Newberne PM. Zinc deficiency and methylbenzylnitrosamine-induced esophageal cancer in rats. J Natl Cancer Inst. 1978 Jul; 61(1):145-50. PMID: 276623.
      View in: PubMed
    Lawrence's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP